Anastrozole and Related Glucuronic Acid Conjugate are Electrophilic Species
Xenobiotica. 2022 Jun 3:1-12. doi: 10.1080/00498254.2022.2086503. Online ahead of print.ABSTRACTAnastrozole (ANA), is an inhibitor of non-steroidal aromatase, widely employed for the treatment of breast cancer. However, ANA-associated liver injury cases have been documented in the application of the drug.The major purposes of the present study were to identify the structure of reactive metabolites derived from ANA and to study related metabolic pathways of ANA.We found ANA itself is an electrophilic species reactive to GSH. ANA can be metabolized to ANA-N+-glucuronide (1) catalyzed by UGT1A4. An ANA GSH conjugate (2) was d...
Source: Xenobiotica - June 3, 2022 Category: Research Authors: Siyu Ding Siyu Liu Yaxuan Chen Ying Peng Jiang Zheng Source Type: research
Anastrozole and related glucuronic acid conjugate are electrophilic species
Xenobiotica. 2022 Jun 13:1-9. doi: 10.1080/00498254.2022.2086503. Online ahead of print.ABSTRACTAnastrozole (ANA), is an inhibitor of non-steroidal aromatase, widely employed for the treatment of breast cancer. However, ANA-associated liver injury cases have been documented in the application of the drug.The major purposes of the present study were to identify the structure of reactive metabolites derived from ANA and to study related metabolic pathways of ANA.We found ANA itself is an electrophilic species reactive to GSH. ANA can be metabolised to ANA-N+-glucuronide (1) catalysed by UGT1A4. An ANA GSH conjugate (2) was d...
Source: Xenobiotica - June 3, 2022 Category: Research Authors: Siyu Ding Siyu Liu Yaxuan Chen Ying Peng Jiang Zheng Source Type: research
Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings
AbstractAnastrozole is a third-generation aromatase inhibitor that exerts potent anti –breast cancer effects. This trial aimed to explore the pharmacokinetics (PK) and safety with bioequivalence of orally administered anastrozole provided by 2 sponsors in healthy volunteers.Two separate open-label, randomized, single-dose, crossover-design studies consisting of a fasting study (n = 23) and a fed study (n = 23, 1 participant withdrew before taking medication) were conducted. In each study, healthy volunteers were randomized to receive the test product (Haizheng Pharmaceutical Group) followed by the reference drug (AstraZe...
Source: Clinical Pharmacology in Drug Development - June 1, 2022 Category: Drugs & Pharmacology Authors: Ying Wang,
Tongtong Wang,
Han Fang,
Hui Huang,
Lijuan Fang,
XuanGuo Zhang Tags: Original Article Source Type: research
Novel Meibomian Gland and Tarsal Conjunctival Changes Associated with Trastuzumab, Pertuzumab, and Anastrozole Treatment for Metastatic HER2 Positive Breast Cancer: A Case Report and Literature Review
The aim of the study was to report a case of severe meibomian gland dysfunction (MGD) and conjunctival changes associated with trastuzumab, pertuzumab, and anastrozole therapy in a HER-2 positive breast cancer patient. A 57-year-old white woman was treated with trastuzumab and pertuzumab biological and anastrozole endocrine therapy for metastatic breast cancer for several months. She suffered from intense eye pain and foreign body sensation. On the ocular surface, severe MGD developed without corneal lesions. On the tarsal conjunctiva, circumscribed lesions evolved 6 months after receiving anticancer therapy. After biopsy,...
Source: Case Reports in Oncology - May 5, 2022 Category: Cancer & Oncology Source Type: research
Low-Grade Serous Ovarian Carcinoma: a Retrospective Study from a Tertiary Cancer Institute
AbstractThe aim of this study was to evaluate the clinico-pathological behaviour and treatment patterns of low-grade serous carcinomas (LGSC) of ovary treated at a regional cancer centre. A retrospective analysis was done for the histopathology-proven cases of low-grade serous ovarian carcinoma, treated at a tertiary cancer institute between January, 2010, and September, 2019. There were 28 patients identified from the medical records with low-grade serous ovarian carcinoma. Median age of the patients was 43 years [22–79 years]. Average BMI was 22.3 ± 4.0 kg/m2 [range 15.2 –31.2]. Twenty-one (75%) were parous ...
Source: Indian Journal of Surgical Oncology - May 5, 2022 Category: Cancer & Oncology Source Type: research
Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings
AbstractAnastrozole is a third-generation aromatase inhibitor that exerts potent anti –breast cancer effects. This trial aimed to explore the pharmacokinetics (PK) and safety with bioequivalence of orally administered anastrozole provided by 2 sponsors in healthy volunteers.Two separate open-label, randomized, single-dose, crossover-design studies consisting of a fasting study (n = 23) and a fed study (n = 23, 1 participant withdrew before taking medication) were conducted. In each study, healthy volunteers were randomized to receive the test product (Haizheng Pharmaceutical Group) followed by the reference drug (AstraZe...
Source: Clinical Pharmacology in Drug Development - April 29, 2022 Category: Drugs & Pharmacology Authors: Ying Wang,
Tongtong Wang,
Han Fang,
Hui Huang,
Lijuan Fang,
XuanGuo Zhang Tags: Original Article Source Type: research
Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings
Clin Pharmacol Drug Dev. 2022 Apr 29. doi: 10.1002/cpdd.1099. Online ahead of print.ABSTRACTAnastrozole is a third-generation aromatase inhibitor that exerts potent anti-breast cancer effects. This trial aimed to explore the pharmacokinetics (PK) and safety with bioequivalence of orally administered anastrozole provided by 2 sponsors in healthy volunteers.Two separate open-label, randomized, single-dose, crossover-design studies consisting of a fasting study (n = 23) and a fed study (n = 23, 1 participant withdrew before taking medication) were conducted. In each study, healthy volunteers were randomized to receive the tes...
Source: Clinical Breast Cancer - April 29, 2022 Category: Cancer & Oncology Authors: Ying Wang Tongtong Wang Han Fang Hui Huang Lijuan Fang XuanGuo Zhang Source Type: research
Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings
Clin Pharmacol Drug Dev. 2022 Apr 29. doi: 10.1002/cpdd.1099. Online ahead of print.ABSTRACTAnastrozole is a third-generation aromatase inhibitor that exerts potent anti-breast cancer effects. This trial aimed to explore the pharmacokinetics (PK) and safety with bioequivalence of orally administered anastrozole provided by 2 sponsors in healthy volunteers.Two separate open-label, randomized, single-dose, crossover-design studies consisting of a fasting study (n = 23) and a fed study (n = 23, 1 participant withdrew before taking medication) were conducted. In each study, healthy volunteers were randomized to receive the tes...
Source: Clinical Genitourinary Cancer - April 29, 2022 Category: Cancer & Oncology Authors: Ying Wang Tongtong Wang Han Fang Hui Huang Lijuan Fang XuanGuo Zhang Source Type: research
Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings
Clin Pharmacol Drug Dev. 2022 Apr 29. doi: 10.1002/cpdd.1099. Online ahead of print.ABSTRACTAnastrozole is a third-generation aromatase inhibitor that exerts potent anti-breast cancer effects. This trial aimed to explore the pharmacokinetics (PK) and safety with bioequivalence of orally administered anastrozole provided by 2 sponsors in healthy volunteers.Two separate open-label, randomized, single-dose, crossover-design studies consisting of a fasting study (n = 23) and a fed study (n = 23, 1 participant withdrew before taking medication) were conducted. In each study, healthy volunteers were randomized to receive the tes...
Source: Clinical Breast Cancer - April 29, 2022 Category: Cancer & Oncology Authors: Ying Wang Tongtong Wang Han Fang Hui Huang Lijuan Fang XuanGuo Zhang Source Type: research
Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings
Clin Pharmacol Drug Dev. 2022 Apr 29. doi: 10.1002/cpdd.1099. Online ahead of print.ABSTRACTAnastrozole is a third-generation aromatase inhibitor that exerts potent anti-breast cancer effects. This trial aimed to explore the pharmacokinetics (PK) and safety with bioequivalence of orally administered anastrozole provided by 2 sponsors in healthy volunteers.Two separate open-label, randomized, single-dose, crossover-design studies consisting of a fasting study (n = 23) and a fed study (n = 23, 1 participant withdrew before taking medication) were conducted. In each study, healthy volunteers were randomized to receive the tes...
Source: Clinical Genitourinary Cancer - April 29, 2022 Category: Cancer & Oncology Authors: Ying Wang Tongtong Wang Han Fang Hui Huang Lijuan Fang XuanGuo Zhang Source Type: research
Efficacy and safety of letrozole or anastrozole in the treatment of male infertility with low testosterone ‐estradiol ratio: a meta‐analysis and systematic review
Conclusion: AIs may be effective in the treatment of male infertility. For male infertile patients planning assisted reproduction, discontinuation of AIs for 2 –7 days prior to sperm retrieval may increase the success rate of fertilization. Further studies with larger sample sizes are needed to validate these findings.This article is protected by copyright. All rights reserved (Source: Andrology)
Source: Andrology - April 20, 2022 Category: Urology & Nephrology Authors: Bin Guo,
Jiao ‐jiao Li,
Ya‐ling Ma,
Yu‐tao Zhao,
Jian‐guo Liu Tags: ORIGINAL ARTICLE Source Type: research
Poorly Differentiated Scrotal Carcinoma With Apocrine Immunophenotype
Abstract:
Cutaneous carcinoma of the scrotum is rare with the most common type being squamous cell carcinoma. Here, we report 6 cases of poorly differentiated carcinoma with apocrine immunophenotype. Mean age at presentation was 68 years (range: 31–91 years). Clinical presentation included eczematous rash over mass, scrotal cyst, ulcerated mass, and mass. Tumor size ranged from 1.2 to 5.5 cm (average 2.5 cm). The tumors were solid with involvement of the dermis/hypodermis and composed of cords and nests of eosinophilic cells displaying nuclei with prominent nucleoli and surrounded by desmoplastic stroma. Focal squamo...
Source: The American Journal of Dermatopathology - March 24, 2022 Category: Pathology Tags: Original Study Source Type: research
Anastrozole-related dermatitis with mainly unilateral distribution
Australas J Dermatol. 2022 Feb 23. doi: 10.1111/ajd.13813. Online ahead of print.NO ABSTRACTPMID:35196401 | DOI:10.1111/ajd.13813 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - February 23, 2022 Category: Dermatology Authors: Takahiro Mizuta Miyuki Kato Source Type: research
Anastrozole-related dermatitis with mainly unilateral distribution
Australas J Dermatol. 2022 Feb 23. doi: 10.1111/ajd.13813. Online ahead of print.NO ABSTRACTPMID:35196401 | DOI:10.1111/ajd.13813 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - February 23, 2022 Category: Dermatology Authors: Takahiro Mizuta Miyuki Kato Source Type: research
Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Non-Steroidal Aromatase Inhibitors in Post-Menopausal Women with Breast Cancer: A Network Meta-Analysis
Conclusion: Lower incidence of bone-related safety events in patients treated with exemestane was observed. Further head-on studies are confirmation. (Source: Breast Care)
Source: Breast Care - February 18, 2022 Category: Cancer & Oncology Source Type: research
